יחס שווי פעילות לרווח לפני ריבית, מסים ופחת Keros Corp (KROS)

The low predictability of Keros Therapeutics (KROS) cash flows is driven by its laboratory research stage, which is confirmed by the EV/EBITDA value including total debt shown on this GURU.Markets chart, where 0.00 captures the current state of the parameter. Profit prospects are based on therapies for anemia and bone pathologies, while investment inflows rely on clinical data under full FDA oversight.

Assessing the investment reliability of equity assets begins with analyzing the ratio of total enterprise value to operating profit before depreciation and interest. For Keros Therapeutics (KROS), which is developing a TGF-beta protein modulation platform, the company's EV/EBITDA value on this chart reflects the efficiency of capitalizing innovations in rare disease therapy, allowing for a determination of the asset's overvaluation relative to its actual cash flow.